HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 90.4%

Neg 90.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.

Comments

No comments yet. Be the first!